JP6836825B2 - 水不溶性またはわずかに水溶性の薬剤の水可溶性を改善するための方法 - Google Patents

水不溶性またはわずかに水溶性の薬剤の水可溶性を改善するための方法 Download PDF

Info

Publication number
JP6836825B2
JP6836825B2 JP2017566080A JP2017566080A JP6836825B2 JP 6836825 B2 JP6836825 B2 JP 6836825B2 JP 2017566080 A JP2017566080 A JP 2017566080A JP 2017566080 A JP2017566080 A JP 2017566080A JP 6836825 B2 JP6836825 B2 JP 6836825B2
Authority
JP
Japan
Prior art keywords
water
concentration
propylene glycol
drugs
estin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017566080A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019501861A5 (https=
JP2019501861A (ja
Inventor
グラッサウアー，アンドレアス
プリィシゥル‐グラッサウアー，エバ
ボーデンタイヒ，アンジェリカ
モロクッティ‐クルツ，マーティーナ
ナコーウィッチ，サビン
カインツ，コーネリア
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Marinomed Biotech AG
Original Assignee
Marinomed Biotechnologie GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Marinomed Biotechnologie GmbH filed Critical Marinomed Biotechnologie GmbH
Publication of JP2019501861A publication Critical patent/JP2019501861A/ja
Publication of JP2019501861A5 publication Critical patent/JP2019501861A5/ja
Application granted granted Critical
Publication of JP6836825B2 publication Critical patent/JP6836825B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/0291—Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A61K8/602—Glycosides, e.g. rutin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/10—General cosmetic use

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Birds (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Anesthesiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
JP2017566080A 2015-07-16 2016-07-15 水不溶性またはわずかに水溶性の薬剤の水可溶性を改善するための方法 Active JP6836825B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201514801578A 2015-07-16 2015-07-16
US14/801,578 2015-07-16
PCT/EP2016/066999 WO2017009480A1 (en) 2015-07-16 2016-07-15 Method for improving aqueous solubility of water-insoluble or slightly water-soluble drugs

Publications (3)

Publication Number Publication Date
JP2019501861A JP2019501861A (ja) 2019-01-24
JP2019501861A5 JP2019501861A5 (https=) 2019-07-11
JP6836825B2 true JP6836825B2 (ja) 2021-03-03

Family

ID=56418519

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017566080A Active JP6836825B2 (ja) 2015-07-16 2016-07-15 水不溶性またはわずかに水溶性の薬剤の水可溶性を改善するための方法

Country Status (29)

Country Link
EP (1) EP3324933B1 (https=)
JP (1) JP6836825B2 (https=)
KR (1) KR102615005B1 (https=)
CN (1) CN107847440B (https=)
AU (1) AU2016293125B2 (https=)
CA (1) CA2992376C (https=)
CL (1) CL2018000032A1 (https=)
CO (1) CO2018001460A2 (https=)
CY (1) CY1124322T1 (https=)
DK (1) DK3324933T3 (https=)
EA (1) EA036233B1 (https=)
ES (1) ES2844581T3 (https=)
HR (1) HRP20210333T1 (https=)
HU (1) HUE053116T2 (https=)
IL (1) IL256882B (https=)
LT (1) LT3324933T (https=)
MA (1) MA42472B1 (https=)
MX (1) MX379341B (https=)
MY (1) MY196065A (https=)
NZ (1) NZ738592A (https=)
PH (1) PH12018500042A1 (https=)
PL (1) PL3324933T3 (https=)
PT (1) PT3324933T (https=)
RS (1) RS61561B1 (https=)
SA (1) SA518390688B1 (https=)
SI (1) SI3324933T1 (https=)
UA (1) UA123312C2 (https=)
WO (1) WO2017009480A1 (https=)
ZA (1) ZA201708594B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12377046B1 (en) 2019-04-24 2025-08-05 Wellomics LLC Delivery system matrices

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108143713A (zh) * 2018-01-04 2018-06-12 南方医科大学南方医院 一种增加羟喜树碱溶解度的方法
CN110074385B (zh) * 2019-05-21 2022-05-31 绥化市蓝源生物工程有限公司 一种生物碱溶解纳他霉素的生物溶剂及其应用
KR20220022829A (ko) * 2020-08-19 2022-02-28 주식회사 모든바이오 글리시리진 및 수용성 약물을 포함하는 나노 입자, 이를 포함하는 약제학적 조성물 및 이들의 제조 방법
CN114588118B (zh) * 2022-01-25 2023-05-23 武汉爱民制药股份有限公司 一种注射用七叶皂苷钠复方制剂
KR102922176B1 (ko) * 2022-07-08 2026-02-04 한국생산기술연구원 소수성 약물 전달을 위한 금-히알루론산 나노입자의 제조방법
EP4431082A1 (en) * 2023-03-13 2024-09-18 Marinomed Biotech AG Aqueous composition comprising budesonide
EP4516289A1 (en) 2023-08-30 2025-03-05 SPH Sine Pharmaceutical Laboratories Co., Ltd Antiviral nasal spray comprising favipiravir
CN117562911B (zh) * 2023-12-07 2024-06-04 海南医学院 化合物tigloside在制备治疗和/或预防骨关节炎药物中的用途
WO2025133675A1 (en) * 2023-12-20 2025-06-26 Melikoglu, Ahmet Method for producing nasal formulation comprising aescin and rutin
EP4696300A1 (en) 2024-08-14 2026-02-18 Marinomed Biotech AG Aqueous composition comprising fluticasone
KR102907892B1 (ko) * 2025-01-09 2026-01-12 주식회사 한바이오 가용성을 높인 피레스로이드계의 보건용 스프레이 살충제 제조방법

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1119957A (en) 1979-12-04 1982-03-16 Martin Whitefield Steroid compositions
US4782047A (en) 1986-05-22 1988-11-01 Syntex Pharmaceuticals International Ltd. Aqueous steroid formulations for nasal administration
US4868170A (en) 1987-11-13 1989-09-19 E. R. Squibb & Sons, Inc. Steriod lotion formulation
JPH1025255A (ja) * 1996-07-11 1998-01-27 Taisho Pharmaceut Co Ltd 溶解性の改善された難溶性薬剤
FR2799369B1 (fr) 1999-10-08 2001-12-21 Oreal Association d'escine et de sulfate de dextran et son utilisation
US7125564B2 (en) 2001-02-16 2006-10-24 Lavipharm Laboratories, Inc. Water soluble and palatable complexes
JP4000283B2 (ja) * 2002-08-07 2007-10-31 丸善製薬株式会社 甘草油性抽出物の可溶化組成物、並びに飲料、液状調味料、化粧品及び医薬部外品
US7897587B2 (en) 2004-09-03 2011-03-01 Nycomed Us Inc. Topical dermatological formulations and use thereof
JP5128801B2 (ja) * 2006-10-16 2013-01-23 フロイント産業株式会社 高水分散性粉末とその製造方法
JP6265624B2 (ja) * 2012-05-11 2018-01-24 ロート製薬株式会社 ルリコナゾール含有外用医薬組成物
US9907846B2 (en) * 2013-04-01 2018-03-06 Mx Adjuvac Ab Nanoparticles, composed of sterol and saponin from Quillaja saponaria Molina for use in pharmaceutical compositions
CN103271891B (zh) * 2013-04-28 2016-01-06 福建南方制药股份有限公司 人参皂苷纳米胶束及其制备方法、应用和药物组合物
CN103520081B (zh) * 2013-09-27 2015-10-28 无限极（中国）有限公司 一种调节皮肤免疫力、延缓皮肤老化的外用护肤品

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12377046B1 (en) 2019-04-24 2025-08-05 Wellomics LLC Delivery system matrices

Also Published As

Publication number Publication date
UA123312C2 (uk) 2021-03-17
BR112018000613A2 (pt) 2018-09-18
IL256882B (en) 2021-12-01
KR102615005B1 (ko) 2023-12-18
HK1253027A1 (zh) 2019-06-06
DK3324933T3 (da) 2021-01-18
PL3324933T3 (pl) 2021-08-02
IL256882A (en) 2018-03-29
EP3324933A1 (en) 2018-05-30
MY196065A (en) 2023-03-13
CY1124322T1 (el) 2022-07-22
PH12018500042A1 (en) 2018-07-09
ES2844581T3 (es) 2021-07-22
HRP20210333T1 (hr) 2021-04-16
ZA201708594B (en) 2019-06-26
EA036233B1 (ru) 2020-10-16
CA2992376A1 (en) 2017-01-19
HUE053116T2 (hu) 2021-06-28
EP3324933B1 (en) 2020-12-16
JP2019501861A (ja) 2019-01-24
CL2018000032A1 (es) 2018-11-16
WO2017009480A1 (en) 2017-01-19
EA201890194A1 (ru) 2018-10-31
CN107847440A (zh) 2018-03-27
CO2018001460A2 (es) 2018-05-10
SA518390688B1 (ar) 2022-03-13
SI3324933T1 (sl) 2021-04-30
MX2018000286A (es) 2018-02-19
AU2016293125B2 (en) 2021-05-06
MX379341B (es) 2025-03-10
CA2992376C (en) 2023-06-20
MA42472A (fr) 2018-05-30
NZ738592A (en) 2021-12-24
AU2016293125A1 (en) 2018-01-18
RS61561B1 (sr) 2021-04-29
CN107847440B (zh) 2021-06-25
KR20180054569A (ko) 2018-05-24
PT3324933T (pt) 2021-01-28
MA42472B1 (fr) 2021-02-26
LT3324933T (lt) 2021-04-26

Similar Documents

Publication Publication Date Title
JP6836825B2 (ja) 水不溶性またはわずかに水溶性の薬剤の水可溶性を改善するための方法
CN105392469A (zh) 包含二甘醇单乙醚或其他烷基衍生物的药物活性剂的组合物
US11179465B2 (en) Topical compositions comprising a corticosteroid
CA2526616A1 (en) Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
KR20150112975A (ko) 경구 및 비경구적 전달을 위한 클로피도그렐 유리 염기의 안정한 약학 조성물
NZ584544A (en) Novel taxane compositions comprising lecithin and an anionic surfactant
US11510859B2 (en) Method for improving aqueous solubility of water-insoluble or slightly water-soluble drugs
AU2018353360A1 (en) Aqueous compositions comprising bilastine and mometasone
JP2003342171A (ja) ディスラノール投与のための組成物
JP2019048890A (ja) 泡状外用医薬組成物
WO2007086582A1 (ja) ２２－オキサ－１α,２５－ジヒドロキシビタミンＤ3を含有する水中油型乳剤性ローション剤およびそれを用いた皮膚疾患の治療方法
BR112018000613B1 (pt) Método para melhorar a solubilidade aquosa de fármacos insolúveis em água ou levemente solúveis em água
HK1253027B (zh) 改善水不溶性或微水溶性药物的水溶性的方法
KR101510764B1 (ko) 사이클로스포린 함유 안약 조성물 및 그 제조방법
EP3893845B1 (en) Composition comprising dutasteride
HK1145807A (en) Novel taxoid-based compositions
HK1218081B (en) Stable pharmaceutical composition of clopidogrel free base for oral and parenteral delivery

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180115

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190610

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190610

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200422

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200526

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200825

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201016

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210126

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210206

R150 Certificate of patent or registration of utility model

Ref document number: 6836825

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250